“What 3D ultrasound will allow us to do is to help us use the information that we get from mammography and integrate that information together with the information we get from ultrasound to find more cancers.”
“Mammography is an effective tool at finding breast cancer, but it doesn’t work equally well in everyone. Recently completed studies demonstrated with the addition of somo•v* ABUS we find about 30 percent more cancers in women who have a normal mammogram, normal physical examination and dense breasts. For the more than 40 percent of women who have dense breasts, this is a significant advancement in their breast healthcare.”
Dr. Rachel Brem, M.D, Principal Investigator of the SOMO-INSIGHT Clinical Study
"We are very excited to become part of GE Healthcare's team. The worldwide resources of GE Healthcare will allow us to expand and accelerate our efforts to commercialize the recently FDA-Approved somo•v® ABUS. With our combined resources and capabilities, we have the opportunity to make a significant impact on breast cancer detection and patient outcomes around the world. We are thrilled to have the opportunity to continue to develop new technologies, products and applications for breast cancer screening. The entire U-Systems team looks forward to joining GE."
Ron Ho, U-Systems President and CEO